Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age over 18.~* Histological diagnosis of adenocarcinoma of rectum.~* Locally advanced/ poor prognosis primary rectal cancer defined by MRI criteria of any of the categories below;~  * Tumour within 2 mm of mesorectal fascia ie circumferential resection margin threatened~ * Any T3 tumour at/below levatores~ * T3c tumour at any other level ie tumour extends \>5 mm into peri-rectal fat~ * T4 tumour~ * Any T stage with 4 or more involved lymph nodes~* WHO performance status 0, 1 or 2.~* No evidence of metastatic disease as determined by CT scan of chest, abdomen, pelvis or other investigations such as PET scan or biopsy if required.~* Adequate bone marrow function with platelets \> 100 X 109/l; WBC \> 3 X 109/l; neutrophils \> 1.5 X 109/l~* Normal renal function, with serum creatinine within the normal range or calculated creatinine clearance \>50 ml/min.~* Adequate hepatic function with serum total bilirubin \< 1.5 X upper limit of normal range.~* No concurrent uncontrolled medical conditions~* No previous malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix~* Adequate contraceptive precautions if relevant~* Informed written consent~Exclusion Criteria:~* Medical or psychiatric conditions that compromise the patient's ability to give informed consent~* Presence of metastatic disease or recurrent rectal tumour~* Renal impairment (creatinine clearance\<30 ml/min)~* Pregnancy or breast feeding~* Patients with a lack of physical integrity of the upper gastrointestinal tract, or known malabsorption syndromes~* Participation in any investigational drug study within the previous 4 weeks.~* Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia even if controlled with medication) or myocardial infarction within the last 12 months)~* Patients with any symptoms or history of peripheral neuropathy.~* Prior pelvic radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).